Search
-
Bringing Healthcare Segmentations to Life: The Dawn of the GenAI-Powered Persona
Enter the age of generative AI, ushering in a new era of possibility with the advent of the persona bot – a tool with the potential to revolutionise how pharmaceutical companies activate and leverage segmentation data.
-
A Dose of Digital: Can Pharma Make DTx a Healthy Business?
Digital therapeutics (DTx) are emerging as a potential game-changer in healthcare, offering evidence-based digital interventions to help prevent, manage, or treat specific conditions.
-
The time is now: Telehealth and rise of virtual care
Virtual care has gained increased importance during coronavirus, but will this bring about a permanent shift in remote healthcare.
-
Multi-source healthcare data
The world of pharma business insight is likely to change as it embraces a multi-data source reality.
-
Uncover the power of the patient voice: Healthcare-focused Social Intelligence & Text Analytics
The rich wealth of unstructured and unrequested data on social media offers critical input to your brand’s story. Ipsos’ healthcare-focused Social Intelligence & Text Analytics offering, powered by Synthesio’s leading technology, unlocks the opportunities within unstructured data, bringing you unparalleled insights into authentic patient experiences and perceptions.
-
Conquering Complexity: The coming revolution in oncology biomarker testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.
-
Is the Behavioural Lens Out of Focus?
How to make behaviour work in CPG, financial services, technology and retail? Using behavioural science to get closer to the consumer.
-
Who Will Win the Race to Treat NASH?
Non-alcoholic Steatohepatitis, or NASH, is a liver disease characterized by rising prevalence, low diagnosis and a lack of therapies approved for treatment. All of these factors combine to make NASH a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. Accordingly, the race is now on among several pharma companies to develop the first effective pharmacotherapy to treat NASH.
-
Harnessing Complexity: Companion Diagnostics in Oncology
As an increasing number of drugs gain approval for patients whose cancers have certain molecular characteristics, the promise of truly personalised medicine is edging closer towards reality.